Journal of Clinical Medicine
September 19, 2025
Ana Flavia Burlec, Cornelia Mircea, Irina Macovei et al.
Background/Objectives: This study examines the development of clinical trials investigating psilocybin for the treatment of psychopathologies, with a comparative focus on the United States (US) and the European Union (EU). The objective is to identify regional differences in trial progression, research infrastructure, and regulatory frameworks. Methods: A mixed-methods approach was applied,...
TIPS - Trends in Pharmacological Sciences
September 16, 2025
Sonia Sonda, Diana Pendin, Stefano Comai et al.
11 citations
Psilocybin, a serotonergic psychedelic, is gaining attention for its rapid and sustained therapeutic effects in depression and other hard-to-treat neuropsychiatric conditions, potentially through its capacity to enhance neuronal plasticity. While its neuroplastic and therapeutic effects are commonly attributed to serotonin 2A (5-HT 2A ) receptor activation, emerging evidence reveals a more...
Journal of Affective Disorders
September 16, 2025
Sami George Sabbah, Sophie Li, Sabrina Wong et al.
2 citations
Although these findings suggest psilocybin is associated with dynamic and temporally distinct neuroplastic changes linked to clinical improvement, several limitations must be acknowledged. Many studies reused overlapping datasets with high exploratory flexibility and risk of bias. The generalizability of results is therefore constrained. Future research should emphasize independent datasets,...
ACS Omega
September 15, 2025
Taynah Pereira Galdino, Antônio Braz de Medeiros Bisneto, Marcelo Da Silva Pedro et al.
1 citation
High Resolution Image Download MS PowerPoint Slide Mental disorders of the global population have been evaluated statistically by decades. Psilocybin has medicinal properties with potential pharmaceutical applications for treatment of psychological disorders. This component is present naturally in mushrooms of the Psilocybe genus and is primarily responsible for their psychoactive properties....
New Zealand Medical Journal
September 15, 2025
Ben Beaglehole, Jenni Manuel
aim: To provide a balanced account of psilocybin treatment of depression for expectations to be appropriately set. method: Review and discussion of key psilocybin efficacy studies. Reporting of side effects and risk of harm with psychedelic treatments. Comparisons and contrasts with ketamine studies of treatment-resistant depression (TRD). result: Early psilocybin studies offer promise but...
Research Square
September 12, 2025
Christina Chwyl, Angelica Spata, Will Lucas et al.
preprint
Abstract Background Self-transcendent and mystical experiences may be key mechanisms underlying psychedelics’ therapeutic effects, yet how these experiences differ across substances remains unclear. This study compared mystical and self-transcendent experiences across psilocybin, 3,4-Methylenedioxymethamphetamine (MDMA), and cannabis in a diverse, community-based sample, while accounting for...
Healthcare
September 12, 2025
Ariane Bélanger, Sue-Ling Chang, Jean-François Stephan et al.
1 citation
Background/Objectives: Given the limitations of traditional approaches to treating existential distress in seriously ill patients, psilocybin-assisted therapy (PAT) has emerged as a promising treatment option. However, weighing up the potential risks and benefits of this approach can be challenging for both healthcare professionals and patients. Decision aids can play a key role in supporting...
Frontiers in Psychiatry
September 11, 2025
Małgorzata Wierzbicka, Renata Kopczyk, Alexander L. Gerlach et al.
correction
[This corrects the article DOI: 10.3389/fpsyt.2025.1591864.].
Journal of Psychedelic Studies
September 11, 2025
Ron Shore, K. Dobson, Nina Thomson et al.
Abstract Background and Aims Psilocybin is a psychedelic compound that may hold promise for a wide range of human health conditions, yet the identification of therapeutic processes and mechanisms of action remains exploratory. We conducted a scoping review of pre-clinical behavioural investigations of psilocybin in non-human animals to identify behavioural effects, studies completed,...
JAMA Network Open
September 11, 2025
Richard B. van Breemen, Daniel Simchuk, Bjorn Fritzsche et al.
1 citation
This case series evaluates the active constituents of unregulated psilocybin mushroom edibles.